2026 regulatory explainer · compounded GLP-1s · research use only
Compounded GLP-1s in 2026: what the FDA's 503B proposal actually changed.
In 2026 the legal pathways that let compounding pharmacies and outsourcing facilities supply low-cost semaglutide and tirzepatide narrowed sharply. On April 30, 2026 the FDA formally proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the list of bulk drug substances that registered outsourcing facilities are allowed to compound from — after concluding there was 'no clinical need' for facilities to compound these drugs from bulk (FDA press announcement, April 30, 2026; Federal Register, Vol. 91, No. 84, May 1, 2026). Because the branded-drug shortages that had earlier opened a separate compounding pathway were declared resolved in 2025, this proposal would close one of the last remaining bulk-compounding routes for these three GLP-1 molecules at 503B facilities. This page is a plain, sourced explainer of what was proposed, the timeline, and — importantly — why 'research-use-only' compounds are a legally and practically separate category from the compounding-pharmacy medicines the rule addresses. It is a research and regulatory reference, not medical, dosing, or purchasing advice, and Titan does not sell semaglutide, tirzepatide, or liraglutide. The only in-stock compound referenced here, retatrutide, is a different, investigational molecule supplied strictly for research use — not a substitute for any medication.
What the FDA actually proposed (April 30, 2026)
The FDA announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, stating it 'did not identify a clinical need for outsourcing facilities to compound' these three drugs from bulk drug substances (FDA press announcement, April 30, 2026). The formal notice appeared in the Federal Register (Vol. 91, No. 84, May 1, 2026), which identifies these three substances as ones the agency 'proposes not to include' on the list. This is a proposal open to public comment, not yet a final determination — but it signals FDA's current position clearly.
Research-use policy →Why: the 'clinical need' standard — and what it excludes
Under section 503B of the FD&C Act, a bulk substance goes on the list only when the FDA determines there is a genuine clinical need for outsourcing facilities to compound with it. Crucially, the agency stated it does not count supply backorders, the convenience of a ready-to-use form, or the lower cost of a compounded product versus the FDA-approved branded drug as part of 'clinical need.' So the everyday reasons people relied on compounded GLP-1s — price and availability — are explicitly outside the legal test the FDA applied.
Evaluating vendors in 2026 →The timeline: comments through June 29, 2026, then a final call
The FDA opened a public comment docket and invited interested parties to submit comments through June 29, 2026. After reviewing the docket, the agency said it may seek input from the Pharmacy Compounding Advisory Committee (PCAC) before issuing a final determination in the Federal Register — either finalizing the exclusion as proposed or modifying it in light of new evidence. In other words: the direction is set, but the final, binding determination follows the comment-and-review process rather than taking effect on the announcement date.
The 2026 vendor shakeout →What this does NOT mean for research compounds
This is the part most write-ups blur. The 503B bulks-list decision governs how outsourcing facilities may compound finished medicines from semaglutide, tirzepatide, and liraglutide for patient use. Research-use-only (RUO) reference compounds are a separate category entirely: they are sold strictly for laboratory research, explicitly not for human or animal consumption, and are not compounded medicines, prescriptions, or FDA-approved drugs. Treating an RUO compound as a legal or medical replacement for a compounded prescription would be a category error — the two are governed by different rules and intended for different uses.
Why RUO is a separate category →Retatrutide: a different molecule, an investigational research compound
Retatrutide is not one of the three drugs in the FDA proposal and is not a compounded version of them. It is a distinct synthetic triple-incretin agonist (active at the GLP-1, GIP, and glucagon receptors) that appears in published phase-II/III clinical research on incretin pharmacology. It is investigational — not FDA-approved, not a weight-loss drug, and not a treatment. Titan stocks retatrutide only as a research-use-only compound (10 mg lyophilized vial), supplied for laboratory research and explicitly not for human consumption. It is referenced here because it is a GLP-1-class research molecule people studying this space ask about — not as an alternative to any medication.
Retatrutide (RUO) — $199.99 →For a research compound, identity is the variable that matters
If you are sourcing any GLP-1-class research compound, the honest quality question is identity and purity, not marketing. A larger synthetic peptide can be mis-synthesised or truncated and still pass a bare purity number, so identity should be confirmed by mass spectrometry against the expected sequence, not by a purity percentage alone. Titan supplies retatrutide with a lot-matched, in-house release sheet (HPLC purity plus mass-spec identity) available on request. No third-party certificate is claimed — the verifiable edge is a real, lot-matched in-house release document, framed honestly.
How to vet a source →The detail, in plain terms
The 2026 GLP-1 compounding change, at a glance.
Points below summarise the FDA's April 2026 proposal on compounded GLP-1s and how it relates — and does not relate — to research-use-only compounds. This is a regulatory reference reproduced for research purposes, not legal, medical, or purchasing advice. Titan does not sell semaglutide, tirzepatide, or liraglutide.
- What was proposed
- FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk drug substances — FDA press announcement, April 30, 2026.
- Where it was published
- Federal Register, Vol. 91, No. 84 (May 1, 2026), identifying the three substances FDA 'proposes not to include' on the 503B Bulks List.
- The legal test applied
- Section 503B 'clinical need' standard. FDA stated it does NOT count supply backorders, convenience of a ready-to-use form, or lower cost versus the approved branded drug as 'clinical need.'
- Comment deadline
- Public comments accepted through June 29, 2026 via the FDA docket, before a final determination is made.
- Next steps
- FDA may seek Pharmacy Compounding Advisory Committee (PCAC) input, then publish a final determination in the Federal Register — finalizing as proposed or modifying it based on the record.
- Why the shortage pathway had already closed
- 503B facilities can also compound from a bulk substance if the drug is on FDA's shortage list at the time. The semaglutide/tirzepatide shortages were declared resolved in 2025, which had already ended that separate pathway; this proposal addresses the bulks-list route.
- Scope — what it covers
- Compounding of finished medicines by outsourcing facilities from these three GLP-1 substances. It is about medicines for patient use.
- Scope — what it does not cover
- Research-use-only reference compounds, which are sold for laboratory research, explicitly not for human/animal consumption, and are not compounded medicines, prescriptions, or approved drugs — a legally separate category.
- Retatrutide's status
- A distinct investigational triple-incretin agonist (GLP-1/GIP/glucagon); not one of the three drugs in the proposal, not FDA-approved, not a weight-loss drug. Titan stocks it strictly as an RUO research compound — not a substitute for any medication.
- Sourcing quality note
- For any GLP-1-class research compound, identity via mass spectrometry matters more than a purity number alone. Titan: lot-matched in-house HPLC + mass-spec release sheet on request; no third-party certificate claimed.
Questions researchers ask
Before you order.
- What did the FDA change about compounded GLP-1s in 2026?
- On April 30, 2026 the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the list of bulk drug substances that registered outsourcing facilities may compound from — after finding 'no clinical need' for facilities to compound these drugs from bulk (FDA press announcement, April 30, 2026; Federal Register Vol. 91, No. 84, May 1, 2026). Combined with the 2025 resolution of the branded-drug shortages, which had ended a separate compounding pathway, the proposal would narrow the legal routes for outsourcing facilities to bulk-compound these three GLP-1 drugs. It is a proposal open to public comment, not yet a final rule.
- Is compounded semaglutide or tirzepatide banned now?
- Not by a single final action as of this writing. What happened is a proposed FDA determination (April 2026) to keep semaglutide, tirzepatide, and liraglutide off the 503B bulks list, with public comments accepted through June 29, 2026 and a final determination to follow, possibly after Pharmacy Compounding Advisory Committee input. Practically, the earlier shortage-based pathway already closed when FDA declared the shortages resolved in 2025. The precise legal status depends on the specific facility type (503A vs 503B) and the final determination — this page is a research and regulatory reference, not legal or medical advice, so verify current status with primary FDA sources.
- Why did the FDA say there is 'no clinical need'?
- Under section 503B, a bulk substance is added to the list only when the FDA finds a genuine clinical need for outsourcing facilities to compound with it. The agency stated it does not count supply backorders, the convenience of a ready-to-use form, or the lower cost of a compounded product versus the FDA-approved branded drug as part of that test. Because FDA-approved semaglutide, tirzepatide, and liraglutide products are available, the agency did not identify a clinical need for facilities to compound these three from bulk. In short, price and availability — the reasons many people used compounded versions — are outside the legal standard the FDA applied.
- Does this affect research-use-only peptides like retatrutide?
- No — and conflating the two is a common error. The 503B decision governs how outsourcing facilities may compound finished medicines from semaglutide, tirzepatide, and liraglutide for patient use. Research-use-only compounds are a separate category: they are sold strictly for laboratory research, explicitly not for human or animal consumption, and are not compounded medicines, prescriptions, or FDA-approved drugs. Retatrutide in particular is not one of the three drugs in the proposal; it is a distinct investigational molecule. An RUO compound is not a legal or medical replacement for a compounded prescription.
- What is retatrutide, and is it a replacement for compounded semaglutide?
- Retatrutide is a synthetic triple-incretin agonist active at the GLP-1, GIP, and glucagon receptors, studied in published phase-II/III clinical research on incretin pharmacology. It is investigational — not FDA-approved, not a weight-loss drug, and not a treatment — and it is a different molecule from the three GLP-1 drugs in the FDA proposal. It is not a replacement or alternative for compounded semaglutide, tirzepatide, or liraglutide, and nothing here should be read that way. Titan stocks retatrutide solely as a research-use-only compound (10 mg lyophilized), for laboratory research and explicitly not for human consumption.
- If I'm sourcing a GLP-1-class research compound, what should I check?
- For a larger synthetic peptide, identity matters more than a headline purity number: a mis-synthesised or truncated sequence can still post a high HPLC purity figure while being the wrong molecule, so identity should be confirmed by mass spectrometry against the expected sequence. Ask for lot-matched release documentation rather than a generic certificate. Titan supplies retatrutide with a lot-matched, in-house release sheet (HPLC purity plus mass-spec identity) on request; no third-party certificate is claimed. This is a sourcing-quality note for research use, not a purchasing recommendation or medical advice.